ARGX

argenx SE Healthcare - Biotechnology Investor Relations →

NO
59.3% ABOVE
↑ Moving away Was 54.6% last week
-15% -10% -5% 0% 5% 10% 15%+
Signal Threshold $602.58
14-Week RSI 58
Rel. Volume (14w) This week's trading vs. the 14-week average 1.1x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.00

argenx SE (ARGX) closed at $960.04 as of 2026-11-13, trading 59.3% above its 200-week moving average of $602.58. The stock moved further from the line this week, up from 54.6% last week. The 14-week RSI sits at 58, indicating neutral momentum.

Trading volume is running at 1.1x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.00 ratio) is neutral — neither side is clearly dominating.

In 447 weeks of available data, ARGX has never crossed below its 200-week moving average. This suggests the stock has maintained a strong long-term uptrend throughout its history.

With a market cap of $60.4 billion, ARGX is a large-cap stock. The stock trades at 178.3x book value.

Share count has increased 11.7% over three years, indicating dilution.

Over the past 8.7 years, a hypothetical investment of $100 in ARGX would have grown to $1088, compared to $324 for the S&P 500. That represents an annualized return of 31.7% vs 14.5% for the index — confirming ARGX as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: ARGX vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

Dislocation Scores Experimental

Each score measures deviation from ARGX's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

Yield Dislocation N/A Dividend yield vs own 10-yr norm
Drawdown Score +0.19σ Distance from line vs own history
Sector-Relative -0.66σ Vs sector median this week
Buyback Acceleration -2.0pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History N/A Vs own recent annual mean
Earnings Quality Improving Accrual gap trend (-12.1pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Historical Touches

ARGX has not crossed below its 200-week moving average in the available data (447 weeks).

Frequently Asked Questions

Is ARGX below its 200-week moving average?

No. argenx SE (ARGX) is currently 59.3% above its 200-week moving average of $602.58. It would need to fall to $602.58 to cross below the line.

What is ARGX's 200-week moving average price?

argenx SE's 200-week moving average is $602.58 as of 2026-11-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

Is ARGX a good value right now?

Here's what our data says about ARGX as of 2026-11-13: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 58. Price-to-book is 178.3x. This is not a buy or sell recommendation — always do your own research.

How does ARGX compare to the S&P 500?

Over the past 8.7 years, $100 invested in ARGX would have grown to $1088, compared to $324 for the S&P 500. That's 31.7% annualized vs 14.5% for the index. ARGX has outperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-11-13